PeptiDream identifying peptide candidates against Bayer targets

Bayer AG (Xetra:BAYN) and PeptiDream Inc. (Tokyo:4587) partnered to use PeptiDream's Peptide Discovery Platform System to identify macrocyclic peptide candidates against cancer and cardiovascular disease targets from Bayer. The pharma will also have an option to negotiate for an extension of the license to peptide-drug conjugates, diagnostics, bioimaging and agricultural applications.

PeptiDream will receive an undisclosed upfront payment and R&D funding, and is eligible for $1.1 billion in milestones, plus royalties. Bayer will have rights to compounds developed under the deal...